AEACEI
MCID: ANG049
MIFTS: 40

Angioedema Induced by Ace Inhibitors (AEACEI)

Categories: Bone diseases, Cardiovascular diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioedema Induced by Ace Inhibitors

MalaCards integrated aliases for Angioedema Induced by Ace Inhibitors:

Name: Angioedema Induced by Ace Inhibitors 56 73
Angioedema Induced by Ace Inhibitors, Susceptibility to 56 29 6 39
Acquired Angioedema 58 71
Aeacei 56 73
Renin-Angiotensin-Aldosterone System-Blocker-Induced Angioneurotic Edema 58
Renin-Angiotensin-Aldosterone System-Blocker-Induced Angioedema 58
Drug-Related Side Effects and Adverse Reactions 43
Acquired Angioedema with Normal C1 Inhibitor 58
Acquired Non Histamine-Induced Angioedema 58
Ace Inhibitor-Related Acquired Angioedema 58
Raas-Blocker-Induced Angioneurotic Edema 58
Acquired Bradykinine-Induced Angioedema 58
Acquired Angioedema with Normal C1inh 58
Acquired C1 Inhibitor Deficiency 58
Acei-Related Acquired Angioedema 58
Raas-Blocker-Induced Angioedema 58
Acquired Angioneurotic Edema 58
Ae-Acei 73
Rae 58
Aae 58

Characteristics:

Orphanet epidemiological data:

58
acquired angioedema
Inheritance: Not applicable; Age of onset: Adult;
renin-angiotensin-aldosterone system-blocker-induced angioedema
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare allergic disease


External Ids:

OMIM 56 300909
MESH via Orphanet 44 C538173
ICD10 via Orphanet 33 T78.3
UMLS via Orphanet 72 C2931758
SNOMED-CT via HPO 68 400075008 41291007
UMLS 71 C2931758

Summaries for Angioedema Induced by Ace Inhibitors

OMIM : 56 Approximately 40 million people take ACE inhibitors (ACEi) to treat hypertension and cardiovascular disease. A small proportion of white patients who take ACEi (0.1-0.7%) develop angioedema (AEACEI) (Israili and Hall, 1992; Vleeming et al., 1998), a potentially life-threatening side effect characterized by swelling of the face, lips, tongue, and airway that can lead to suffocation and death if severe. ACEi-associated angioedema is 4 to 5 times more prevalent among African Americans (Brown et al., 1996; Coats, 2002). Other risk factors include female sex, smoking, immunosuppressant therapy, and seasonal allergies. The pathophysiology of ACEi-associated angioedema is thought to be related to increased circulating bradykinin, which is normally degraded by ACE. During pharmacologic ACE inhibition, bradykinin is primarily degraded by aminopeptidase P (summary by Duan et al., 2005 and Woodard-Grice et al., 2010). Aminopeptidase P is encoded by 3 genes: XPNPEP1 (602443) on chromosome 10q25, XPNPEP2 (300145) on chromosome Xq25, and XPNPEP3 (613553) on chromosome 22q13. (300909)

MalaCards based summary : Angioedema Induced by Ace Inhibitors, also known as angioedema induced by ace inhibitors, susceptibility to, is related to acquired angioedema and acquired angioedema type 1. An important gene associated with Angioedema Induced by Ace Inhibitors is XPNPEP2 (X-Prolyl Aminopeptidase 2). The drugs Ceftazidime and Tetracaine have been mentioned in the context of this disorder. Affiliated tissues include tongue, testes and breast, and related phenotypes are angioedema and ascites

UniProtKB/Swiss-Prot : 73 Angioedema induced by ACE inhibitors: A potentially life-threatening side effect of ACE inhibitors that appears in a subset of patients taking these drugs for hypertension and cardiovascular disease treatment. AEACEI is characterized by swelling of the face, lips, tongue, and airway that can lead to suffocation and death if severe.

Related Diseases for Angioedema Induced by Ace Inhibitors

Diseases related to Angioedema Induced by Ace Inhibitors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Related Disease Score Top Affiliating Genes
1 acquired angioedema 12.7
2 acquired angioedema type 1 12.5
3 acquired angioedema type 2 12.5
4 acquired angioedema with c1inh deficiency 12.3
5 angioedema, hereditary, type i 11.6
6 reactive angioendotheliomatosis 11.3
7 hereditary angioedema 10.5
8 complement component 4, partial deficiency of 10.5
9 c1 inhibitor deficiency 10.5
10 angioedema 10.4
11 lymphoproliferative syndrome 10.3
12 marfan syndrome 10.3
13 cardiac arrest 10.3
14 aortic valve insufficiency 10.3
15 esophageal cancer 10.3
16 multiple chemical sensitivity 10.3
17 lymphoma 10.2
18 hydrops, lactic acidosis, and sideroblastic anemia 10.2
19 marginal zone b-cell lymphoma 10.1
20 urticaria 10.1
21 west nile virus 10.1
22 bacterial infectious disease 10.1
23 mediastinitis 10.1
24 haemophilus influenzae 10.1
25 thyroid carcinoma 10.1
26 sjogren syndrome 10.1
27 autoimmune disease 10.1
28 leukemia, chronic lymphocytic 10.1
29 splenic marginal zone lymphoma 10.1
30 lymphocytic leukemia 10.1
31 vitiligo-associated multiple autoimmune disease susceptibility 6 10.1
32 vitiligo-associated multiple autoimmune disease susceptibility 1 10.1
33 graves' disease 10.1
34 food allergy 10.1
35 complement deficiency 10.1
36 thrombophilia due to thrombin defect 10.0
37 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
38 antiphospholipid syndrome 10.0
39 melkersson-rosenthal syndrome 10.0
40 mantle cell lymphoma 10.0
41 facial paralysis 10.0
42 echinococcosis 10.0
43 monoclonal paraproteinemia 10.0
44 cryoglobulinemia 10.0
45 lymphosarcoma 10.0
46 blepharochalasis and double lip 9.8
47 systemic lupus erythematosus 9.8
48 anemia, autoimmune hemolytic 9.8
49 lymphoma, hodgkin, classic 9.8
50 myelofibrosis 9.8

Graphical network of the top 20 diseases related to Angioedema Induced by Ace Inhibitors:



Diseases related to Angioedema Induced by Ace Inhibitors

Symptoms & Phenotypes for Angioedema Induced by Ace Inhibitors

Human phenotypes related to Angioedema Induced by Ace Inhibitors:

58 31 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 angioedema 58 31 Very frequent (99-80%) HP:0100665
2 ascites 58 Occasional (29-5%)
3 abdominal pain 58 Very frequent (99-80%)
4 edema 58 Very frequent (99-80%)
5 urticaria 58 Occasional (29-5%)
6 intestinal obstruction 58 Occasional (29-5%)
7 facial edema 58 Occasional (29-5%)
8 laryngeal edema 58 Occasional (29-5%)
9 intestinal edema 58 Occasional (29-5%)

Clinical features from OMIM:

300909

GenomeRNAi Phenotypes related to Angioedema Induced by Ace Inhibitors according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased hepcidin::fluc mRNA expression GR00253-A 8.62 G6PD XPNPEP2

Drugs & Therapeutics for Angioedema Induced by Ace Inhibitors

Drugs for Angioedema Induced by Ace Inhibitors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 469)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
2
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
3
Meclizine Approved Phase 4 569-65-3 4034
4
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
5
Desflurane Approved Phase 4 57041-67-5 42113
6
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
7
Ribavirin Approved Phase 4 36791-04-5 37542
8
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
9
Etomidate Approved Phase 4 33125-97-2 36339 667484
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
12
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
13
Thrombin Approved, Investigational Phase 4
14
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
15
Digoxin Approved Phase 4 20830-75-5 30322 2724385
16
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
17
Pseudoephedrine Approved Phase 4 90-82-4 7028
18
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
19
Ephedrine Approved Phase 4 299-42-3 9294
20
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
21
Cyclopentolate Approved Phase 4 512-15-2 2905
22
Phenylephrine Approved Phase 4 59-42-7 6041
23
Racepinephrine Approved Phase 4 329-65-7 838
24
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
25
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
26
Trandolapril Approved Phase 4 87679-37-6 5484727
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
28
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
29
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
30
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
31
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
32
Losartan Approved Phase 4 114798-26-4 3961
33
Eprosartan Approved Phase 4 133040-01-4 5281037
34
Fosinopril Approved Phase 4 98048-97-6 55891
35
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
36
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
37
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
38
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
39
Enalaprilat Approved Phase 4 76420-72-9 6917719
40
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
41
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
42
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
43
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
44
Azilsartan medoxomil Approved, Investigational Phase 4 863031-21-4
45
Ramipril Approved Phase 4 87333-19-5 5362129
46
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
48
Acetaminophen Approved Phase 4 103-90-2 1983
49
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
50
Ibuprofen Approved Phase 4 15687-27-1 3672

Interventional clinical trials:

(show top 50) (show all 229)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of MR and APDT Vaccine Unknown status NCT01830257 Phase 4
2 Adverse Drug Reactions of Different Brands of Ceftazidime Injection Unknown status NCT00173901 Phase 4 ceftazidime
3 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
4 Motion Sickness Medications and Vestibular Time Constant Unknown status NCT03270839 Phase 4 Bonine 25Mg Chewable Tablet;Kwells;Placebo Oral Tablet
5 The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting Unknown status NCT02213718 Phase 4 Desflurane;propofol;sufentanil
6 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
7 Pulpal Blood Flow With the Use of Intra-nasal Anesthetic: a Randomized Double-blind Crossover Study Unknown status NCT03368391 Phase 4 tetracaine HCl and oxymetazoline HCL;2% Lidocaine with 1:100,000 epinephrine;3% Mepivacaine with 1:100,000 epinephrine;saline intranasal;saline infiltration
8 Evaluation of CYP4A11 and CYP4F2 Gene Variants as Makers in Edema and Elevated Blood Pressure Occurrence After Nonsteroidal Anti-inflammatory (NSAID) Use Completed NCT02779530 Phase 4 Diclofenac
9 Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions of Aspirin Co-administration on the PK/PD of Clopidogrel and PK of Digoxin in Healthy Volunteers Completed NCT01775839 Phase 4 Aspirin+Clopidogrel/Digoxin(oral);Aspirin+Clopidogrel/Digoxin(IV)
10 Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants Completed NCT02720328 Phase 4
11 Aminotransferase Trends During Prolonged Therapeutic Acetaminophen Dosing Completed NCT00743093 Phase 4 acetaminophen;placebo
12 Safety and Immunogenicity of Adjuvanted Versus High-Dose Inactivated Influenza Vaccines in Older Adults Completed NCT03183908 Phase 4
13 A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen Completed NCT01679964 Phase 4 Raltegravir switch
14 An Open-label, Non-randomized Study to Monitor for Adverse Drug Reactions Among Patients Administered Fedoruk-manufactured [F-18]-FDG Injection Completed NCT02811185 Phase 4 [F-18]-Fludeoxyglucose
15 Title of Study: Adverse Drug Event (ADE) Incidence in Older Patients Following Hospital Admission and Pharmacist Review to Older Persons' Prescriptions and Its' Effect on ADE Reduction in Hospital: a Randomised Controlled Trial Completed NCT01467128 Phase 4
16 Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Using STOPP/START Criteria Completed NCT01467050 Phase 4
17 Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia. Recruiting NCT03638726 Phase 4 Atropine sulfate and epinephrine;Topical cyclopentolate and phenylephrine
18 A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. Recruiting NCT03191201 Phase 4 Ferric Carboxymaltose;0.9% sodium chloride solution
19 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
20 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
21 Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics? - A Pilot Study. Optional Deoxyribo-Nucleic Acid Donation for the Study of Hypertension. Recruiting NCT01715584 Phase 4
22 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
23 Optimal Method of Pain Control After Minimally Invasive Coronary Artery Bypass Grafting Terminated NCT01770236 Phase 4 IV acetaminophen
24 Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy Terminated NCT02296840 Phase 4 Ibuprofen;Hydrocodone-Acetaminophen
25 Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger® Withdrawn NCT01374061 Phase 4
26 Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding Unknown status NCT01628068 Phase 3
27 A Phase III Investigation Of Topical Application Of RX0041-002 On Safety And Efficacy In Local (Topical) Anesthesia For Diagnostic Procedures And Surgeries On Or Through The Accessible Mucous Membranes Of The Nasal Cavities Completed NCT02667054 Phase 3 RX0041 4%;Placebo;RX0041 8%
28 Improving Safety by Basic Computerizing Outpatient Prescribing Completed NCT01091038 Phase 2, Phase 3
29 Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer Completed NCT01080547 Phase 3 XELOX Chemotherapy;mFolfox6 chemotherapy
30 Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer Completed NCT00017004 Phase 3 Cisplatin
31 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
32 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
33 Women's Hospital, Zhejiang University School of Medicine Recruiting NCT03885388 Phase 2, Phase 3 MTX;MTX+ACTD
34 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
35 An Open,Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs Unknown status NCT01965275 Phase 2 Erlotinib or Gefitinib
36 Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Patients Unknown status NCT02324803 Phase 2 pazopanib
37 EFFECTIVENESS OF MARY D'UOL REPAIR BALM FOR PREVENTING AND / OR REDUCING TOXICITY SKIN IN PATIENTS WITH CANCER AND TREATMENT WITH ANY Antineoplastic Agent. RANDOM CLINICAL TRIAL. Unknown status NCT02036957 Phase 1, Phase 2
38 Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia Unknown status NCT02024568 Phase 2 Pregabalin;Placebo
39 ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13-CIS RETINOIC ACID WITH OR WITHOUT ALPHA TOCOPHEROL OR OBSERVATION Completed NCT00002586 Phase 2 13-cis retinoic acid
40 Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study Completed NCT02447679 Phase 2 thalidomine;tegafur-uracil
41 Prospective Exploratory Dose-finding Study in Neonates Receiving a Single Intravenous Propofol Bolus for Endotracheal Intubation During (Semi-)Elective INSURE Procedure or Non-INSURE Procedures in Neonates Completed NCT01621373 Phase 2 propofol administration
42 The Study of Efficacy and Adverse Effects of Prapchompoothaweep Remedy Crude Drug and Loratadine for Treatment in Allergic Rhinitis Patients (Clinical Trials Phase II) Completed NCT03640273 Phase 2 Prapchompoothaweep remedy;Loratadine 10 Mg
43 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery Patients Randomized to Different Postoperative Anticoagulant Regimens Completed NCT03212365 Phase 2 Fixed dose;Variable dose
44 Repetitive Electrostatic Pressurised Intraperitoneal Aerosol Chemotherapy With Oxaliplatin (ePIPAC-OX) as a Palliative Monotherapy for Isolated Unresectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Single-arm, Phase II Study (CRC-PIPAC) Completed NCT03246321 Phase 2
45 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00119431 Phase 2 C1 inhibitor concentrate
46 Efficacy and Safety of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis Recruiting NCT03392311 Phase 1, Phase 2 Calcipotriol ointment
47 Efficacy and Safety of Expanded Umbilical Cord Mesenchymal Stem Cells On Patients With Moderate to Severe Psoriasis Recruiting NCT03745417 Phase 1, Phase 2
48 A Multicenter, Phase Ib/II Trial of Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GISTs) Recruiting NCT04138381 Phase 1, Phase 2 Selinexor;Imatinib
49 Safety and Efficacy of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Moderate to Severe Psoriasis Recruiting NCT03265613 Phase 1, Phase 2
50 Adoptive TIL Therapy With Low-dose IFN-alpha Plus Anti-PD1 in Metastatic Melanoma Recruiting NCT03638375 Phase 1, Phase 2 Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha

Search NIH Clinical Center for Angioedema Induced by Ace Inhibitors

Cochrane evidence based reviews: drug-related side effects and adverse reactions

Genetic Tests for Angioedema Induced by Ace Inhibitors

Genetic tests related to Angioedema Induced by Ace Inhibitors:

# Genetic test Affiliating Genes
1 Angioedema Induced by Ace Inhibitors, Susceptibility to 29 XPNPEP2

Anatomical Context for Angioedema Induced by Ace Inhibitors

MalaCards organs/tissues related to Angioedema Induced by Ace Inhibitors:

40
Tongue, Testes, Breast, Liver, Bone, Heart, Kidney

Publications for Angioedema Induced by Ace Inhibitors

Articles related to Angioedema Induced by Ace Inhibitors:

(show all 14)
# Title Authors PMID Year
1
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. 56 6
21898657 2011
2
Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. 56 6
20625347 2010
3
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. 56 6
16175507 2005
4
Omapatrilat--the story of Overture and Octave. 56
12243845 2002
5
Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. 56
12086766 2002
6
Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. 56
10458510 1999
7
ACE inhibitor-induced angioedema. Incidence, prevention and management. 56
9530537 1998
8
Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. 56
8689816 1996
9
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. 56
1616218 1992
10
[Tranexamic acid as first-line emergency treatment for episodes of bradykinin-mediated angioedema induced by ACE inhibitors]. 61
29735174 2018
11
Angioedema. 61
28818177 2017
12
Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare? 61
20163043 2009
13
[Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases]. 61
10198947 1999
14
[Behçet's disease and angioedema induced by ACE-inhibitors: 2 unusual pathological pictures]. 61
9409950 1997

Variations for Angioedema Induced by Ace Inhibitors

ClinVar genetic disease variations for Angioedema Induced by Ace Inhibitors:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 G6PD NM_000402.4(G6PD):c.653C>T (p.Ser218Phe)SNV Pathogenic/Likely pathogenic 100057 rs5030868 X:153762634-153762634 X:154534419-154534419
2 XPNPEP2 NG_011479.1:g.2846C>ASNV risk factor 11567 rs3788853 X:128870791-128870791 X:129736814-129736814

Expression for Angioedema Induced by Ace Inhibitors

Search GEO for disease gene expression data for Angioedema Induced by Ace Inhibitors.

Pathways for Angioedema Induced by Ace Inhibitors

GO Terms for Angioedema Induced by Ace Inhibitors

Sources for Angioedema Induced by Ace Inhibitors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....